Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $164.4 Million in 2025 and projected to reach to $283 Million by 2030, representing a compound annual growth rate of 11.5%. Rest Of Europe's HPV and Pap Smear test market is positioned for sustained growth through 2030, driven by strengthened healthcare infrastructure, rising cervical cancer awareness, and improved screening accessibility.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- This 11.5% compound annual growth rate reflects increasing awareness of cervical cancer screening and HPV prevention across the region.
- Rest Of Europe is benefiting from strengthened healthcare infrastructure, rising adoption of advanced diagnostic technologies, and supportive regulatory frameworks that prioritize women's health initiatives. The market expansion in Rest Of Europe is driven by growing cervical cancer incidence, improved access to screening programs, and integration of HPV testing into routine preventive care protocols.
- Rest Of Europe's healthcare systems are increasingly recognizing the clinical and economic value of early detection through HPV and Pap testing.
- Between 2025 and 2030, Rest Of Europe is expected to see significant investment in diagnostic capabilities and public health campaigns, positioning the region as a key growth market within Europe's broader cervical cancer screening landscape..
Key Market Statistics
- CAGR (2025-2030) 11.5% CAGR
- Market Size, 2025 ~USD 164.4 Million
- Forecast, 2030 ~USD 283 Million
- Country Rest Of Europe
Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Strong Regional Growth Trajectory :
Rest Of Europe's HPV and Pap Smear test market is expanding at 11.5% CAGR, outpacing the global average of 10%, driven by enhanced cervical cancer screening initiatives and improved healthcare accessibility across the region.
Significant Market Expansion :
Market valuation is projected to grow from USD 164.4 million in 2025 to USD 283.0 million by 2030, representing a 72% increase over five years and reflecting sustained investment in women's health diagnostics.
Healthcare Infrastructure Development :
Rest Of Europe is benefiting from strengthened healthcare infrastructure, including expanded screening programs, improved laboratory capabilities, and better integration of HPV testing into national cervical cancer prevention strategies.
Rising Awareness and Prevention Focus :
Increasing public awareness of HPV-related cervical cancer risks and the effectiveness of preventive screening is driving higher adoption rates across Rest Of Europe, supported by regional health authority campaigns.
Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- The region's 11.5% CAGR reflects growing investment in women's health diagnostics and preventive care initiatives.
- National screening programs are increasingly incorporating HPV testing alongside traditional Pap smears, enhancing detection accuracy and patient outcomes. Key growth drivers include aging populations requiring regular screening, healthcare policy reforms prioritizing cancer prevention, and technological advancements in diagnostic testing.
- Rest Of Europe's diverse healthcare systems are progressively standardizing screening protocols and expanding coverage to underserved populations.
- This market expansion presents significant opportunities for diagnostic manufacturers, healthcare providers, and laboratory service providers operating across the region..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- Rest Of Europe's HPV and Pap smear market will grow from USD 164.4 million (2025) to USD 283.0 million (2030) at an 11.5% CAGR.
- Rest Of Europe is experiencing increased adoption of HPV testing as a primary screening method, replacing traditional Pap smear-only protocols.
- Rest Of Europe's market growth is supported by enhanced healthcare funding, public awareness campaigns, and integration of screening into national health programs.
- Rest Of Europe represents a high-growth opportunity within Europe, driven by improving diagnostic infrastructure and rising cervical cancer prevention priorities.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
Target Audience
- Diagnostic Equipment Manufacturers : Need Rest Of Europe market data to assess demand for HPV testing platforms, Pap smear analyzers, and laboratory equipment; understand regional procurement preferences and competitive positioning to drive sales growth.
- Healthcare Service Providers : Require market insights to evaluate screening program expansion opportunities, benchmark service offerings against regional competitors, and optimize resource allocation for cervical cancer prevention initiatives.
- Pharmaceutical & Biotech Companies : Need Rest Of Europe-specific market intelligence to identify opportunities for HPV vaccines, diagnostic reagents, and treatment solutions; understand regional healthcare policies and reimbursement landscapes.
- Healthcare Investors & Private Equity : Seek detailed market forecasts and growth drivers for Rest Of Europe to evaluate investment opportunities in diagnostic companies, screening networks, and women's health service providers in this expanding market.
- Government & Health Policy Organizations : Require comprehensive market data to inform cervical cancer screening policy decisions, budget allocations for prevention programs, and healthcare infrastructure investments across Rest Of Europe.
Key Companies in the Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Reasons to Buy this Report
- Regional Market Sizing & Forecasting : Obtain precise market valuations specific to Rest Of Europe (USD 164.4M in 2025, USD 283M in 2030) with detailed 5-year projections to support strategic planning and investment decisions in this high-growth region.
- Competitive Landscape Intelligence : Understand Rest Of Europe's unique competitive dynamics, key market players, and regional healthcare policies that differentiate this market from global trends, enabling targeted market entry and expansion strategies.
- Growth Driver Analysis : Identify specific factors driving the 11.5% CAGR in Rest Of Europe, including healthcare infrastructure improvements, screening program expansion, and regional awareness initiatives to capitalize on emerging opportunities.
- Regulatory & Healthcare Framework Insights : Access detailed information on Rest Of Europe's diverse healthcare systems, screening protocols, reimbursement structures, and regulatory requirements essential for product development and market commercialization.
- Customer Segmentation & Targeting : Leverage Rest Of Europe-specific audience insights to identify and prioritize high-value customer segments including hospitals, diagnostic laboratories, and healthcare providers for effective go-to-market strategies.
Frequently asked questions
What is the market size of HPV and Pap smear testing in Rest Of Europe?
Rest Of Europe's HPV and Pap smear market was valued at USD 164.4 million in 2025 and is forecast to reach USD 283.0 million by 2030.
What is the expected growth rate for Rest Of Europe's HPV test market?
Rest Of Europe's market is projected to grow at a compound annual growth rate (CAGR) of 11.5% from 2025 to 2030.
What factors are driving market growth in Rest Of Europe?
Rest Of Europe's market growth is driven by increased cervical cancer awareness, improved healthcare access, adoption of advanced HPV testing technologies, and integration of screening into national health programs.
How is Rest Of Europe's market performance compared to global trends?
Rest Of Europe's 11.5% CAGR outpaces the global market CAGR of 10%, indicating stronger regional demand and investment in cervical cancer screening.
What screening methods are most prevalent in Rest Of Europe?
Rest Of Europe is transitioning toward HPV-based primary screening, with increasing adoption of HPV testing alongside or replacing traditional Pap smear protocols in national screening programs.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
